Measles Cases in Ohio: Recommendations for Identification and Prevention

Summary

- Columbus Public Health, Ohio Department of Health (ODH), Centers for Disease Control and Prevention (CDC), and Delaware Public Health District (DPHD) are working closely with clinical and community partners to respond to an ongoing outbreak of measles in central Ohio.
- Worldwide, there is evidence of recent declines in routine immunization coverage with measles containing vaccine (MCV), and large outbreaks of measles have occurred in multiple countries during 2022.
- Healthcare providers should be alert for signs and symptoms of measles, particularly among persons who have not yet received MCV, including those who may have postponed or missed doses. Providers should also consider outreach to patients who are eligible for MCV to encourage routine immunization. DPHD offers MMR vaccination through our clinic. Call 740-368-1700 and select option 5 to make an appointment.
- Measles virus testing is available at the Ohio Department of Health Laboratory (ODHL) for eligible clinical specimens upon approval. Contact DPHD to assist in coordinating testing.

Measles is a Class A reportable disease. If measles is suspected, facilities should implement appropriate infection prevention and control measures and report any case, suspected case, or positive laboratory result immediately to Delaware Public Health District via telephone at 740-815-6518.

Background

Measles is a highly contagious viral respiratory illness. The virus is transmitted through airborne spread of droplet nuclei or direct contact with nasal or throat secretions of infected persons; droplet nuclei can remain suspended in the air for up to two hours. The average incubation period for measles is 14 days, with a range of 7-21 days.

Globally, there is evidence of recent declines in routine immunization coverage with MCV. Cases of measles and large outbreaks continue to be identified in multiple countries, and the risk of measles importations into the U.S. is ongoing.

In early November 2022, ODH was notified of two children presenting to a local pediatric hospital emergency department in Columbus with rash illness consistent with measles. Public health interviews revealed that neither child had documented receipt of MCV, neither child was a contact of a known individual with measles, and neither child had recently traveled domestically or internationally. Both children tested positive for measles by polymerase chain reaction (PCR) testing. Subsequent contact investigations, testing, and epidemiologically linked clinical reports have identified over 40 additional cases in the central Ohio area. There are currently no cases identified in Delaware County, however, many contacts to confirmed cases reside in DPHD jurisdiction. Identified cases in the current outbreak have occurred among partially vaccinated and unvaccinated persons; some individuals were not eligible for any doses because of their age.
**Clinical Recognition**
Measles is characterized by an initial prodrome that typically includes high fever, cough, coryza, and conjunctivitis, followed by the appearance of a maculopapular rash. Communicability is greatest from four days before the onset of rash until four days after the onset of rash.

Given current elevated respiratory virus activity, suspicion for measles should be heightened among patients with clinically compatible measles symptoms who have not yet received MCV, including those who may have postponed or missed doses. For additional clinical information for healthcare providers, please visit the CDC website at https://www.cdc.gov/measles/hcp/index.html.

**Diagnostic Testing**
The most common methods for confirmatory measles testing are detection of IgM antibody in serum and detection of RNA by real-time PCR (RT-PCR) in a respiratory specimen. The preferred specimens for RT-PCR or virus isolation are throat and nasopharyngeal swabs. Clinical specimens for RT-PCR and virus isolation should be collected at the same time as samples for serologic testing. *Specimens for virus isolation and RNA detection should be collected within three days of rash onset.* Detection of measles RNA and measles virus isolation are most successful when samples are collected on the first day of rash through the 3 days following onset of rash. Detection of measles RNA by RT–PCR may be successful as late as 10–14 days post rash onset.

IgM tests are often positive on the day of rash onset. However, up to 20% of tests for IgM may give false negative results in the first 72 hours of rash onset. Therefore, IgM tests that are negative in the first 72 hours after rash onset should be repeated when there is a high clinical index of suspicion for measles. IgM obtained four days after the onset of rash is the preferred laboratory diagnostic procedure. IgM is detectable for at least 28 days after rash onset. If the titer is negative at that time, it can be repeated at seven days, or paired acute and convalescent sera can be tested for an increase in IgG antibody. The acute specimen should be taken as close to rash onset as possible, and the convalescent specimen drawn two weeks after the acute. The latter method is less desirable because of the delay in definitive diagnosis.

Testing for measles virus is available through Ohio Department of Health Laboratory (ODHL) for eligible clinical specimens. To request approval for testing at ODHL, healthcare providers should contact Delaware Public Health District at 740-368-1700 and ask for a member of the Disease Control and Response Unit. If after hours, call 740-815-6518.

**Infection Prevention and Control**
Measles is a vaccine preventable disease. The measles vaccine is highly protective; one dose of measles mumps-rubella (MMR) vaccine provides 93% protection against measles and two doses provide 97% protection. Children are eligible for routine MMR vaccination beginning at 12 months of age or earlier if traveling internationally.

Persons with probable or confirmed measles infection should be isolated, including exclusion from school or childcare center, for four days following the onset of rash. Contacts who might be susceptible should be immunized with measles vaccine as soon as possible after exposure. Measles vaccine given within 72 hours after exposure may prevent or reduce the severity of disease. Immune globulin (IG) can prevent or modify measles in a susceptible person if given within six days of exposure. IG may be especially indicated for susceptible household contacts <1 year of age, pregnant women, or immunocompromised persons, for whom the risk of complications is increased.
**Infection Control in Healthcare Settings**

To minimize the risk of measles transmission in healthcare settings, healthcare personnel should do the following:

1. Query patients with a febrile rash illness about a history of international travel, contact with foreign visitors, transit through an international airport, or possible exposure to a person with measles in the 3 weeks prior to symptom onset. Possibility of measles should be considered for patients with such a history and symptoms consistent with measles.

2. Patients with suspected measles should immediately be provided a face mask to wear, if tolerated. Encourage respiratory etiquette.

3. Do not allow patients with suspected measles to remain in the waiting room or other common areas; **isolate patients with suspected measles immediately in an airborne infection isolation room if one is available.** If such a room is not available, place the patient in a private room with the door closed. For additional infection control information, please refer to the CDC's control measures for measles.

4. If possible, allow only healthcare personnel with documentation of two doses of MMR vaccine or laboratory evidence of immunity to measles (i.e., measles IgG positive) to enter the patient’s room.

5. Healthcare personnel should wear an N95 or higher-level respirator regardless of presumptive evidence of immunity. (A user seal check should be performed each time the respirator is donned.)

6. If possible, do not allow susceptible visitors in the patient room.

7. Do not use the examination room for **at least two hours** after the possibly infectious patient leaves.

8. If possible, schedule patients with suspected measles at the end of the day.

**9. Notify the Delaware Public Health District immediately by telephone at 740-815-6518 about any patients with suspected measles.**

10. Notify any location where the patient is being referred for additional clinical evaluation or laboratory testing about the patient's suspected measles status, and do not refer patients with suspected measles to other locations unless appropriate infection control measures can be implemented at those locations. The patient must wear a mask, if feasible.

11. Instruct patients with suspected measles and exposed persons to inform all healthcare providers of the possibility of measles prior to entering a healthcare facility so appropriate infection control precautions can be implemented.

12. Make note of the staff and other patients or visitors who were in the area during the time the patient with suspected measles was in the facility and for two hours after they left. If measles is confirmed, exposed people will need to be assessed for measles immunity. The Delaware Public Health District’s Disease Control and Response Unit will assist with contact tracing and will be responsible for assessment of immunity and notifying contacts of their exposure.

**References**

This Health Alert adapted from the HAN released by the CDC and ODH on December 1, 2022.